Using Precision Microbiome Profiling to Develop a Biomarker for Immune Checkpoint Inhibitor Response and a Potent Therapeutic Consortium
Time: 9:25 am
day: Day Two
Details:
- Microbiotica’s metagenomic platform in combination with a new microbiome in Melanoma has enabled identification of a microbiome signature of response to Immune Checkpoint Inhibitor consistent across four independent studies
- MB097 is a precision-medicine Live bacterial Therapeutic derived from a microbiome signature
- Human primary immune cell assays and syngeneic models have validated
- MB097 is being scaled up for First-in-human trials to start in 2022
